Get that fiber in
Cancer Res 63(9):23222329 Huang H et al (2015) VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-kappaB-induced endothelial activation
Common (typically mild and transient): Increased appetite (moderate, less than GHRP-6) Flushing and warmth at the injection site or face Transient drowsiness or sleepiness, particularly with evening doses Mild water retention and peripheral edema Increased gastrointestinal motility Less Common: Elevations in cortisol and ACTH (moderate, comparable to hCRH) Mild prolactin elevation (less than TRH-induced levels) Numbness or tingling in extremities Joint stiffness Lightheadedness post-injection Rare or Theoretical Concerns: Impaired glucose metabolism and elevated blood glucose with prolonged use Potential tachyphylaxis (reduced response) with continuous daily dosing Theoretical promotion of existing malignancies through elevated GH/IGF-1 (applies to all GH-elevating compounds) Side effect incidence tends to be lower than with exogenous hGH because GHRP-2 stimulates endogenous GH synthesis within physiological regulatory limits
[14] Most of the urobilinogen is further reduced into stercobilinogen and is excreted through feces (air oxidizes stercobilinogen to stercobilin, which gives feces their characteristic brown color)
They help improve productivity by decreasing accidents, downtime, absenteeism, theft and turnover
No Human Adverse-Event Programme Without a controlled clinical development programme, the frequency and severity of possible adverse reactions cannot be estimated reliably
